At present, it is not known whether undetectable plasma viremia corresponds to an absence of human immunodeficiency virus type 1 (HIV-1) replication in lymphoid tissues. This issue has been explored in 11 subjects with primary HIV-1 infection treated with zidovudine plus didanosine by evaluating virologic markers in blood and lymphoid tissues 9-18 months after initiation of treatment. These markers include plasma viremia, measured with a sensitive assay with a detection limit of 20 HIV-1 RNA copies/mL, infectious virus titers and proviral DNA in lymph node mononuclear cells, and HIV-1 RNA in lymphoid tissue. Five subjects had plasma viremia õ20 copies/mL and showed no evidence of viral replication in lymphoid tissue. Six subjects had both detectable plasma viremia and evidence of HIV-1 RNA in lymphoid tissue. The results indicate that absence of detectable HIV RNA in lymphoid tissue is associated with viremia levels of HIV-1 RNA õ20 copies/mL.
The primary goal of combined antiviral therapy is to achieve lymphoid tissue biopsies were obtained from lymph nodes, tonsils, and adenoids, and viral replication was assessed in complete suppression of viral replication and possibly eradication of human immunodeficiency virus type 1 (HIV-1). Reparallel in blood and lymphoid tissues. cently, several studies showed a dramatic reduction of viremia to levels below the detection limit of currently used assays (i.e., 500 -200 HIV-1 RNA copies/mL of plasma) in HIV-1 -Patients and Methods infected subjects receiving combined antiviral therapy [1 -3] .
Study population. All subjects with primary HIV-1 infection
However, the recent development of a sensitive assay for the referred to us between January 1995 and March 1996 were offered determination of plasma viremia, with a lower detection limit an open-label therapeutic regimen with zidovudine (250 mg twice of 20 copies/mL, demonstrated that 45% of plasma samples a day) and didanosine (200 mg twice a day) [8] . All subjects with viremia õ200 copies/mL, had ú20 HIV-1 RNA copies/ experienced an acute retroviral syndrome at the time of or in the mL of plasma [4] . month preceding initiation of antiviral therapy, except 1 subject To date, it is difficult to assess whether the absence of detectwho was included 2 months after the onset of the acute retroviral able HIV-1 RNA in plasma reflects the situation in other anasyndrome. The subjects were Caucasians; 7 were male and 4 fetomic compartments, such as lymphoid tissue, which is the male, with a mean age at study entry of 37 years (range, 26-54).
primary site for viral spreading and replication [5 -7] . There-HIV-1 infection was acquired through homosexual contacts in 6 subjects and heterosexual contacts in 5. At 9-18 months after fore, it seems crucial to compare the levels of viral replication initiation of treatment, excisional lymph node biopsies were perin blood and lymphoid tissue and to identify plasma viremia formed in the inguinal area in 11 subjects; tonsil and adenoid levels that correspond to undetectable viral replication in biopsies were collected in parallel in 3 of them.
lymphoid tissue.
HIV-1 RNA assay. Viremia levels were determined in batches To address these issues, 11 subjects with primary HIV-1 using EDTA-treated plasma samples, stored in aliquots at 075ЊC, infection receiving combination therapy [8] were enrolled in a using the Amplicor HIV-1 Monitor test (Roche, Basel, Switzerprospective study. At 9 -18 months after treatment initiation, land) according to the manufacturer's instructions, with a detection limit of Ç200 HIV-1 RNA copies/mL. Samples with viremia õ200 copies/mL were retested using a ''boosted'' modification of the Amplicor HIV Monitor test with a detection limit of 20
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HIV-1 RNA copies/mL [4] . plicate as previously reported [9] . The input of cellular DNA was JID 1998; 177 (June) In situ hybridization. In situ hybridization for the detection of
Results

HIV-1 RNA was performed on paraffin-embedded tissue sections
HIV-1 replication in blood. Viral replication in blood was using RNA probes that comprised 90% of the HIV-1 genome, as evaluated, at the time of lymph node collection, via the determipreviously described [5] . The number of individual cells expressnation of plasma viremia. Five of 11 subjects (subjects 1 -5;
ing HIV-1 RNA were quantified by first determining the area of table 1) had levels of plasma viremia õ20 HIV-1 RNA copies/ the biopsy section, using computerized planimetry, followed by mL. Subjects 6 -8 had levels of plasma viremia just above the counting the number of HIV-1 RNA-expressing cells in the biopsy detection limit, ranging between 22 and 25 copies/mL, whereas section, using a darkfield microscope at 1100 magnification. The plasma viremia was ú200 copies/mL in subjects 9 -11 (table sensitivity of the in situ hybridization procedure was determined 1). The sensitive assay allowed the detection of viremia in by constructing a standard containing a known number of HIV-1 virions and was found to correspond to 13 virus particles (5 silver subjects 6 -10, in whom viremia levels were below the detecgrains). HIV-1 RNA-expressing cells were reported as the number tion limit (500 to 200 HIV-1 RNA copies/mL) of the commerof cells per 10 mm 2 .
cial assay. Figure 1A shows the kinetics of plasma viremia in
Infectious HIV-1 titers. Suspensions of LNMC were obthe 5 subjects with õ20 HIV-1 RNA copies/mL at the time of tained after mincing lymph node tissue with a scalpel, teasing lymph node collection. All 5 had plasma viremia of õ20 copout the cells, and isolating them by ficoll-hypaque gradient cenies/mL at 6 months after initiation of combination therapy. HIV-1 RNA were, however, detected in subjects 7 -11 (figure cell -depleted PBMC from HIV-negative donors. Half of the culture medium was replaced with fresh medium twice a week.
2). A second lymph node biopsy was performed in subjects 1
Fresh uninfected PHA-stimulated PBMC were added to the culand 2 at 7 months after the first biopsy. Like the first lymph subjects 6 and 7 and higher in subjects 9 -11 (table 1) . No
Immunologic parameters. CD3, CD4, and CD8 lymphocyte evidence of active viral replication as assessed by coculture counts were determined on fresh material in lymph nodes and was found in subjects 1 -5, whereas virus was isolated in subblood by flow cytometry (Coulter EPICS IV; Instrumente Geselljects 6 -11 (table 1) . Failure to detect HIV-1 replication in schaft, Basel, Switzerland) using fluoresceinated DAKO-CD3, lymph nodes was confined to subjects 1 -5, who had plasma DAKO-CD8, and R-Phycoerythrin DAKO-CD4 (Dako, Glosviremia of õ20 copies/mL.
trup, Denmark). To minimize variations linked to fluctuations
HIV-1 RNA associated with follicular dendritic cells (FDC).
in total lymphocyte counts, results were expressed as the CD4/ CD8 ratio.
Previous studies showed that the diffuse HIV-1 RNA hybrid- ization signal associated with germinal centers corresponded ever, only traces of HIV-1 trapped in the FDC network were observed in tonsil tissue (data not shown) compared with the to HIV-1 virions trapped in the FDC network [5 -7] . In our study, trapping of HIV-1 in the FDC network was either absent presence of both trapped virions and individual cells expressing HIV-1 RNA in lymph node tissue (table 1) . (subjects 1, 3, and 4) or present in traces (subjects 2 and 5) in subjects with plasma viremia of õ20 copies/mL (table 1, figure Proviral HIV-1 DNA. Proviral HIV-1 DNA concentrations in blood were õ3 copies/10 6 PBMC in 4 of 5 subjects with 2). In subject 2, trapping of HIV-1 was no longer detected in the second lymph node biopsy, performed 7 months later. plasma viremia of õ20 HIV-1 RNA copies/mL. Among the subjects with viremia of ú20 copies/mL, proviral DNA in Trapping of HIV-1 in the FDC network was present in all but 1 of the subjects with plasma viremia of ú20 copies/mL (tablood was below the detection limit in subjects 6 -8, with viremia of 20 -30 copies/mL, whereas the highest levels were ble 1).
HIV-1 distribution in lymph nodes, tonsils, and adenoids. observed in subjects 9 -11, with viremia of ú30 copies/mL (table 1) . Proviral DNA was detected in lymph nodes of all Biopsies of tonsils and adenoids were performed in subjects 4 and 9 at the same time as the lymph node biopsy and in subject subjects except 4 and 8 (table 1) . Proviral DNA was significantly higher (6-to 39-fold) in LNMC than in PBMC (table  P2 at decrease of proviral DNA was slower than that of viremia HIV-1 RNA copies/mL of plasma [1 -3] . However, HIV-1 replication in lymphoid tissue was detected in subjects with ( figure 1) . plasma viremia below 500 to 200 copies/mL [11, 12] . The Lymphocyte markers. CD4/CD8 ratios in lymph nodes and results of the present study, performed by using a sensitive blood are reported in table 1. All subjects, regardless of plasma assay with a detection limit of 20 HIV-1 RNA copies/mL, viremia levels, had a higher CD4/CD8 ratio in lymph nodes indicate that the plasma viremia levels corresponding to unthan in blood. However, no significant correlation was observed detectable viral replication in lymphoid tissue, including between the CD4/CD8 ratios in lymph nodes and blood. Sublymph nodes, adenoids, and tonsils, are generally õ20 copjects with no evidence of viral replication in lymph nodes ies/mL. When detectable, viral replication in lymphoid tissue tended to have a higher CD4/CD8 ratio in lymphoid tissue appears to be associated with plasma viremia ú20 copies/ (median, 4.64 vs. 2.51; P Å .07).
mL. It is important to underscore, however, that levels of plasma viremia õ20 copies/mL and undetectable viral repliDiscussion cation in lymphoid tissue do not necessarily reflect complete Viremia levels in blood are routinely measured by comsuppression of viral replication, since the techniques used mercial assays with a lower detection limit of 500 to 200 are limited by their sensitivity and the size of the sample
